Large-cap Healthcare company Teleflex has moved -5.4% so far today on a volume of 326,062, compared to its average of 404,412. In contrast, the S&P 500 index moved 0.5%.
Teleflex trades -6.66% away from its average analyst target price of $262.92 per share. The 13 analysts following the stock have set target prices ranging from $215 to $330, and on average have given Teleflex a rating of buy.
Anyone interested in buying TFX should be aware of the facts below:
-
Teleflex's current price is 90.9% above its Graham number of $128.55, which implies that at its current valuation it does not offer a margin of safety
-
Teleflex has moved -22.5% over the last year, and the S&P 500 logged a change of -17.1%
-
Based on its trailing earnings per share of 8.71, Teleflex has a trailing 12 month Price to Earnings (P/E) ratio of 28.2 while the S&P 500 average is 15.97
-
TFX has a forward P/E ratio of 18.2 based on its forward 12 month price to earnings (EPS) of $13.5 per share
-
The company has a price to earnings growth (PEG) ratio of 1.9 — a number near or below 1 signifying that Teleflex is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.0 compared to its sector average of 4.07
-
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
-
Based in Wayne, the company has 14,000 full time employees and a market cap of $11,510,830,080. Teleflex currently returns an annual dividend yield of 0.5%.